The stock of biotech Arrowhead Pharmaceuticals ( ARWR +23.34%) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company’s shares rose
Why Vera Therapeutics Stock Crushed it Today
If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue.
Nasdaq ISE proposes to raise BlackRock IBIT options trading limits from 250,000 to 1 million
Nasdaq ISE wants to raise the position limit for BlackRock’s IBIT options from 250,000 to 1,000,000 contracts amid soaring demand.
Which Is a Better Investment, Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. Stock?
Learn more about whether Immunocore Holdings plc or Recursion Pharmaceuticals, Inc. is a better investment based on AAII’s A+ Investor grades, which compare both
Donaldson Company: Evaluating a Strong Contender in the Stock Market
Is Donaldson Company a stock worth your attention? Join our experts as they break down its strengths, management, and financials to help you decide
China’s grip on rare earths explained: The leverage behind a global trade war
China’s stranglehold on the rare earths industry — from natural reserves and mining through processing and innovation — is the result of a …
Dow Jones Futures: Robinhood Merry As Stocks Rally Into Thanksgiving; ASML Leads 5 New Buys
Dow Jones futures rose slightly after hours, along with S&P 500 futures and Nasdaq futures. U.S. stock markets will be closed Thursday for the
US stock market up today: S&P 500, Nasdaq and Dow rally for third day as Fed rate-cut bets surge amid growing spotlight on Google-Nvidia AI chip battle
The Dow Jones Industrial Average surged 664 points, marking a three-day winning streak, as investor focus shifted to the Federal Reserve’s potential December rate
Divided Fed sparks surge in rate options hedging as policy uncertainty lingers
Dreyfuss NEW YORK (Reuters) -Conflicting signals from the Federal Reserve on the timing and magnitude of U.S. interest rate cuts have accelerated hedging flows
Long-term uptrend due for an extended pause, says Fairlead’s Stockton on S&P 500
CNBC’s “Closing Bell” team discusses the S&P 500 rebound and where may stocks may go from here as the end of 2025 draws near